Who we are
Board of Recommendation
How to Become a Member
Members’ Activities Calendar
What we do
Policy and Advocacy
Exchange the world
Introduction to IFMSA Exchanges
List of Participating Countries
Research Projects Database
Medical Students International
You are here:
Testing the potential of innovative antioxidant-based drugs as new therapeutic strategy for Parkinson’s disease
Portugal ( PorMSIC) - University Beira Interior, Covilha
CICS-UBI Health Sciences Research Center Av. Infante D. Henrique 6201-506 Covilhã, Portugal
Prof. Ana Paula Duarte
Doctor Ana Clara Cristóvão
French, English, Portuguese
Type of Research Project
- Basic science
What is the background of the project?
Several therapeutic drugs that are in development stages and aim to target neurological disorders exhibit low solubility, requiring the use of vehicles to be solubilized that, in turn, may have a neurotoxic effect. This raises the question if in a regular/daily administration regimen for several years, which is expect to happen in patients, these vehicles may boost neurodegeneration. Therefore, the development of new delivery systems is urgent. The development of ionic liquids (IL) based drugs for pharmaceutical and medical applications are now emerging as a new era for therapeutic strategies. Moreover, our preliminary results showed that antioxidant ILs formulations can be a promising new application to prevent neuronal degeneration in Parkinson disease (PD). With this in mind, our goal is to study the application of new ILs based chemical formulations as carriers for putative neurological diseases drugs and evaluate in in vitro and in vivo models the effectiveness of those formulations to modulate neurogenesis and induce neuroprotection.
What is the aim of the project?
Determination of the neuroprotective effect of new antioxidant chemical formulations, in vitro and in vivo models of Parkinson disease.
What techniques and methods are used?
Cell cultures Rodent models of PD (Parkinson disease) Cell viability tests Reactive oxygen species measurements Immunocytochemistry and immunohistochemistry Fluorescent microscopy
What is the role of the student?
- The tasks will be done under supervision
What are the tasks expected to be accomplished by the student?
Depending on the levels of previous research experience and the time that he/she will stay at CICS-UBI Health Sciences Research Center, the student will follow first master students already working in the project and then will perform lab work and do specific experiments, like cell cultures, cell viability tests, immunostaining, always under supervision, in order to evaluate the neuroprotective effect of new antioxidant chemical formulations and, in that way, develop new therapeutic strategies for Parkinson disease.
Will there be any theoretical teaching provided (preliminary readings, lectures, courses, seminars etc)
Once arrived the student will have key scientific paper to read, related with the subject of the project. Ana Cristóvão will summarize the overall goal of the project.
What is expected from the student at the end of the research exchange? What will be the general outcome of the student?
- The student will prepare a scientific report
What skills are required of the student? Is there any special knowledge or a certain level of studies needed?
To have knowledge in neurobiology and previous experience with cell cultures
Are there any legal limitations in the student’s involvement
Due to patent requirements, associated with the compounds used, the results and knowledge acquired by the students working in this project are confidential and the intellectual property of those will be exclusively of Ana Clara Cristovao. The student cannot communicate either results or knowledge acquired while working in this project without an authorization from Ana Clara Cristovao
Type of students accepted
This project accepts: - Medical students - Graduated students (less than 6 months) - Pre-Medical students from the American-British system
- Esposito E; Cuzzocrea S. “New therapeutic strategy for Parkinson's and Alzheimer's disease” PMID: 20586718
© 2015 - IFMSA.org - Developed by web agency